This study aimed to assess how these changes influenced the prescription patterns of anti-vascular endothelial growth factor (anti-VEGF) agents in both wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) patients. This evidence concerns the gene VEGFA and diabetic macular edema.